Skip to content
Research Article Open access CC BY 4.0

Recent Updates in the Management of HIV Infection

Ravinandan A. P., Reya Merin Biju, G. Mohammed Mustafa, Hunsur Nagendra Vishwas

Journal of Complementary and Alternative Medical Research · pp. 16–23 · Published 23 Jan 2023

10.9734/jocamr/2023/v21i1426

Abstract

Acquired immunodeficiency syndrome (AIDS) is a lethal disease caused by the dreaded pathogen, the human immunodeficiency virus (HIV). Fortunately, antiretroviral therapy (ART) distinctly reduces plasma viral load from the blood and thus mitigates HIV-associated morbidity and mortality. Further, ART also markedly reduces the risk of HIV transmission to sexual partners and infants. Consequently, antiretroviral therapy has converted HIV infection into a manageable chronic condition, with the expectation of life approaching that for people without HIV. However, lack of adherence to treatment results in the development of drug resistance as well as quickens disease development. Therefore, conditions that encourage adherence should be maximized before and after the commencement of antiretroviral therapy. Adverse effects, drug abuse, depression, socioeconomic status, low level of literacy, less social support, and interruptible access to medications are some of the reasons for poor adherence. Frequent monitoring, adequate counselling, and proper social protection help to improve treatment adherence.

HIV AIDS antiretroviral therapy adherence

References (17)

  1. 1 Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis [DOI]
  2. 2 Monitoring selected national HIV prevention and care objectives by using HIV surveillance data : United States and 6 dependent areas, 2015
  3. 3 Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection [DOI]
  4. 4 CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic Suppression [DOI]
  5. 5 Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir [DOI]
  6. 6 Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update [DOI]
  7. 7 Improved Virological Outcomes in British Columbia Concomitant with Decreasing Incidence of HIV Type 1 Drug Resistance Detection [DOI]
  8. 8 Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy [DOI]
  9. 9 Genetic barrier to resistance for dolutegravir.
  10. 10 Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up [DOI]
  11. 11 Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin [DOI]
  12. 12 Fostemsavir: First Approval [DOI]
  13. 13 The Physical, Emotional and Interpersonal Impact of HAART: Exploring the Realities of HIV Seropositive Individuals on Combination Therapy [DOI]
  14. 14 Harnessing the Prevention Benefits of Antiretroviral Therapy to Address HIV and Tuberculosis [DOI]
  15. 15 New WHO Guidelines: Implications on Therapeutics and Monitoring of HIV Infections [DOI]
  16. 16 A Review on Various Aspects of HIV Infection [DOI]
  17. 17 Guidelines for the use of antiretroviral agents in pediatric HIV infection [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

4

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.